Migraine

Among women with prepregnancy migraine diagnosis, rates of gestational hypertension and preeclampsia were 28% and 40% higher, respectively, vs women without migraine.

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.

If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.

Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.

Individuals with migraine were found more likely to have IBS and IBS was more prevalent in those with migraine; both associations were statistically significant.

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.

Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.

Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.

Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.

The first vaccine against COVID-19, 2 new treatments for migraine, a novel topical agent for atopic dermatitis, and 4 more recently approved drugs of interest to primary care.

The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.

Cannabis researchers Drs Carrie Cuttler and Rebecca Craft discuss their findings, their labs at WSU, their new research, and what makes this kind of research a challenge.

Research on pain relief from use of medical cannabis poses myriad challenges. Veteran researchers discuss 2 new studies based on a deep well of user data.

Migraine headaches are a condition commonly seen in primary care. Here is a top-line look at the evidence for efficacy of the wide range of treatments available.

In a phase 2/3 study, nearly half of rimegepant-treated patients demonstrated ≥50% reduction in the number of moderate-to-severe migraine days per month

A family physician with expertise in headache treatment makes the case for appropriate use of opioids in some patients.

Drugs that treat migraine come from a variety of classes and reflect on- and off-label use. How current are you?

The headache community is more than ready for a preventive migraine drug that works. Click through these slides for highlights of recently published trials.

There is a good deal of misinformation available about migraine headaches. Which of these 10 statements are myth and which are fact?

This month’s Special Report post-test allows you to gauge how much you have learned about current approaches to treating migraine headache.

Monoclonal antibodies that inhibit calcitonin gene-related peptide could revolutionize preventive migraine therapy. Here's what you need to know.

Headaches that occur several days before menses as well as disabling headaches on days unrelated to menses... how would you help this young woman?

If the goal of headache therapy for adolescent migraineurs is a pain-free adult life, here's a road map.

From PAINWeek 2017: Reflex vasodilation is out, neurobiologic dysfunction is in as explanation for migraine etiology.

What Rx for adolescent migraineurs? Ideal care for menstrual migraine? Perfect patient for new CGRP inhibitors? Answers in this PCP Special Report.

Headache was a hot topic at the AAN Annual Meeting, and several studies have added to the literature. This slideshow summarizes the latest.

If you know that the FDA approved onabotulinumtoxinA to treat chronic migraine headache but aren't sure how it works, a neurologist explains.